Catherine Wood's ARKG Position Overview
Catherine Wood (via Ark Investment Management LLC) currently holds 7.1K shares of ARK Genomic Revolution ETF (ARKG) worth $195,814, representing 0.00% of the portfolio. First purchased in 2020-Q4, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Catherine Wood has maintained a strategic position in ARKG, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2021, adding 37.5K shares. Largest reduction occurred in Q1 2022, reducing 46.5K shares.
Analysis based on 13F filings available since 2013 Q2
Catherine Wood's ARK Genomic Revolution ETF (ARKG) Holding Value Over Time
Track share changes against reported price movement
Quarterly ARK Genomic Revolution ETF (ARKG) Trades by Catherine Wood
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2020 | +1,670 | New Buy | 1,670 | $93.41 |
| Q1 2021 | +9,065 | Add 542.81% | 10,735 | $88.78 |
| Q2 2021 | -2,344 | Reduce 21.84% | 8,391 | $92.48 |
| Q3 2021 | +7,521 | Add 89.63% | 15,912 | $74.72 |
| Q4 2021 | +37,478 | Add 235.53% | 53,390 | $61.25 |
| Q1 2022 | -46,541 | Reduce 87.17% | 6,849 | $45.99 |
| Q2 2022 | +3,858 | Add 56.33% | 10,707 | $32.22 |
| Q3 2022 | -9,126 | Reduce 85.23% | 1,581 | $32.89 |
| Q4 2022 | +14,553 | Add 920.49% | 16,134 | $28.23 |
| Q1 2023 | -10,102 | Reduce 62.61% | 6,032 | $30.07 |
| Q2 2023 | -2,837 | Reduce 47.03% | 3,195 | $34.09 |
| Q3 2023 | +829 | Add 25.95% | 4,024 | $27.86 |
| Q4 2023 | +5,155 | Add 128.11% | 9,179 | $32.81 |
| Q1 2024 | -1,062 | Reduce 11.57% | 8,117 | $28.76 |
| Q2 2024 | -777 | Reduce 9.57% | 7,340 | $23.48 |
| Q3 2024 | -3,872 | Reduce 52.75% | 3,468 | $25.60 |
| Q4 2024 | +2,521 | Add 72.69% | 5,989 | $23.55 |
| Q1 2025 | -2,097 | Reduce 35.01% | 3,892 | $20.76 |
| Q2 2025 | +429 | Add 11.02% | 4,321 | $24.35 |
| Q3 2025 | +2,730 | Add 63.18% | 7,051 | $27.77 |
Catherine Wood's ARK Genomic Revolution ETF Investment FAQs
Catherine Wood first purchased ARK Genomic Revolution ETF (ARKG) in Q4 2020, acquiring 1,670 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood has held ARK Genomic Revolution ETF (ARKG) for 20 quarters since Q4 2020. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's largest addition to ARK Genomic Revolution ETF (ARKG) was in Q4 2021, adding 53,390 shares worth $3.27 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 7,051 shares of ARK Genomic Revolution ETF (ARKG), valued at approximately $195,814. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ARK Genomic Revolution ETF (ARKG) represents approximately 0.00% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Catherine Wood's peak holding in ARK Genomic Revolution ETF (ARKG) was 53,390 shares, as reported at the end of Q4 2021. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.